Filgrastim Withdrawn Phase 2 Trials for Multiple Myeloma and Plasma Cell Neoplasm / Chronic Myeloproliferative Disorders / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases / Anemias / Malignant Lymphomas / Leukemias Treatment

IndicationsStatusPurposePhase
WithdrawnTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00301912Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
NCT00446173Autologous Stem Cell Transplants for Chronic Myelogenous Leukemia
NCT00005998Peripheral Stem Cell Transplantation With Specially Treated Stem Cells in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease
NCT02961816Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma
NCT00003929Chemotherapy, Filgrastim, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma